Open Trials

At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  With collaborations with Sarah Cannon Research Institute (SCRI) and VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.

BREAST CANCER - NEOADJUVANT

24-301: Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer. Click here to learn more

BREAST CANCER - ADJUVANT

22-326: Phase 3, open-label, randomized study to assess the efficacy and safety of camizestrant (AZD9833, a next-generation, oral selective estrogen receptor degrader) vs standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease (CAMBRIA-2). Click here to learn more

BREAST CANCER - ADVANCED/METASTATIC 

24325: A randomized, open-label, phase 2/3 study of izalontamab brengitecan (BMS-986507) vs treatment of physician's choice in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic Triple Negative Breast Cancer (TNBC) or ER-low, HER2-negative breast cancer who are ineligible for antiPD1/PD-L1 treatment. Click here to learn more

25007: A randomized, open-label, phase 3 study to evaluate Patritumab Deruxtecan monotherapy vs treatment of physician's choice in hormone receptor-positive, HER2-negative, unresectable locally advanced or metastatic breast cancer. Click here to learn more

HEAD & NECK

24-004: A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma. Click here to learn more

LUNG

23-235: Phase 2 Study of EIK1001 in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer. Click here to learn more

24-188: Phase 3, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer (BNT327-03). Click here to learn more

24305: A global, phase 3, randomized, multicenter, open-label study to evaluate the efficacy and safety of Firmonertinib compared with the investigator's choice of Osimertinib or Afatinib as first-line treatment in patients who have locally advanced or metastatic Non-Small-Cell Lung Cancer with  Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations. Click here to learn more

25-091: Phase 3, open-label study to evaluate PF-08046054/SGN-PDL1V versus docetaxel in adult participants with previously-treated programmed cell death ligand (PD-L1) positive non-small cell lung cancer. Click here to learn more

PREVENTION

URCC 19185: Multicenter, randomized trial comparing Brief Behavioral Therapy for Cancer-Related Insomnia (BBT-CI) vs. Healthy Eating Education Learning (HEAL) for treatment of insomnia. Click here to learn more

URCC 22063: Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia. Click here to learn more

WF-2304-172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing benefits and harms of cannabis and cannabinoid use among a cohort of cancer patients treated in community oncology clinics. Click here to learn more